Literature DB >> 9386070

The risks of reoperative coronary artery bypass in chronic ischemic cardiomyopathy: results of the CABG Patch Trial.

I L Kron1, J T Cope, L D Baker, H M Spotnitz.   

Abstract

BACKGROUND: Coronary artery bypass grafting in patients with chronic ischemic cardiomyopathy is increasing in frequency, as is reoperative bypass. However, there exist very little data on early outcomes of patients with severe left ventricular dysfunction undergoing reoperation. Hence, we tested the following hypotheses: (1) in the presence of severe left ventricular dysfunction, repeat coronary bypass carries a higher surgical mortality than the primary operation and (2) among reoperative patients with left ventricular dysfunction, the surgical mortality is higher in those with the lowest preoperative ejection fractions (EFs). METHODS AND
RESULTS: We studied 1429 patients in the CABG Patch Trial, a prospective, controlled study involving 37 centers, to determine rates of early morbidity and mortality in reoperative coronary bypass patients with a reduced EF (<36%). Among patients with an EF <25%, reoperation carried a surgical mortality of 9.3%, compared with 4.3% for first-time bypass (P=NS by chi(2) analysis). With an EF <36%, surgical mortality rates were 12.0% and 4.6% for repeat and primary bypass, respectively (nominal P<.001). Among reoperative patients, there was no difference in surgical mortality at an EF <25% compared with 25% to 35%. Compared with individuals undergoing the primary bypass, reoperative patients were less stable on leaving the operating room and were more than twice as likely to sustain a postoperative myocardial infarction, cardiogenic shock, or open chest resuscitation.
CONCLUSIONS: Reoperative coronary artery bypass grafting in chronic ischemic cardiomyopathy is associated with substantially higher rates of early morbidity and mortality than the initial operation and seems to be primarily attributable to postoperative heart failure.

Entities:  

Mesh:

Year:  1997        PMID: 9386070

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  7 in total

Review 1.  New surgical treatments for heart failure.

Authors:  Mauricio J Garrido; Mehmet C Oz
Journal:  Curr Cardiol Rep       Date:  2002-05       Impact factor: 2.931

2.  Pedicled right internal mammary artery for reoperative off-pump revascularization of left anterior descending coronary artery.

Authors:  Ercan Eren; Mehmet Balkanay; Mehmet Erdem Toker; Berk Ozkaynak; Cuneyt Keles; Mustafa Guler; Cevat Yakut
Journal:  Tex Heart Inst J       Date:  2006

3.  Reoperative coronary artery bypass grafting using a minimally invasive direct coronary artery bypass procedure.

Authors:  T Ueda; T Kawata; K Mizuguchi; T Tsuji; N Tabayashi; T Abe; H Naito; K Nezu; S Taniguchi
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2001-10

4.  The impact of viability assessment using myocardial perfusion imaging on patient management and outcome.

Authors:  Fadi G Hage; Rajesh Venkataraman; Wael Aljaroudi; Paco E Bravo; Joel McLarry; Michael Faulkner; Jaekyeong Heo; Ami E Iskandrian
Journal:  J Nucl Cardiol       Date:  2010-02-26       Impact factor: 5.952

Review 5.  Myocardial revascularization as a therapeutic strategy in the patient with advanced ventricular dysfunction.

Authors:  F A Mitropoulos; J A Elefteriades
Journal:  Heart Fail Rev       Date:  2001-09       Impact factor: 4.214

6.  Preoperative computed tomography is associated with lower risk of perioperative stroke in reoperative cardiac surgery.

Authors:  Damien J Lapar; Gorav Ailawadi; James N Irvine; Christine L Lau; Irving L Kron; John A Kern
Journal:  Interact Cardiovasc Thorac Surg       Date:  2011-03-09

7.  Trends in Reoperative Coronary Artery Bypass Graft Surgery for Older Adults in the United States, 1998 to 2017.

Authors:  Makoto Mori; Yun Wang; Karthik Murugiah; Rohan Khera; Aakriti Gupta; Prashanth Vallabhajosyula; Frederick A Masoudi; Arnar Geirsson; Harlan M Krumholz
Journal:  J Am Heart Assoc       Date:  2020-10-13       Impact factor: 5.501

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.